BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
about
B-Raf and the inhibitors: from bench to bedsideTargeting BRAF in thyroid cancerRole of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trendsSelective use of sorafenib in the treatment of thyroid cancerRobotic transaxillary and retroauricular parathyroid surgeryTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsProgress in molecular-based management of differentiated thyroid cancerBoth BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.Highly prevalent TERT promoter mutations in aggressive thyroid cancers.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialAssociation of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancerOxidative stress: a new risk factor for thyroid cancerBRAF mutations in advanced cancers: clinical characteristics and outcomes2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerBRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.The role of podoplanin in the biology of differentiated thyroid cancers.Association between BRAFV600E mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinomaSenescent tumor cells lead the collective invasion in thyroid cancer.Personalized medicine: the future is not what it used to be.Thyroid cancer: current molecular perspectives.Prognostic utility of BRAF mutation in papillary thyroid cancer.Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancerOccult thyroid carcinomaEvaluation of a thyroid nodule.Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancerMulti-targeted approach in the treatment of thyroid cancer.PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital.MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancersBRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cellsOld and new insights in the treatment of thyroid carcinoma.
P2860
Q21198860-EFFB3757-CD14-4F7E-86A2-72906937C2F1Q24653496-82E58627-726E-496B-A6F1-D13F05027B4DQ26749311-9149C740-A170-4C71-8C5C-CCB36A95813FQ26752891-DA9416D7-F3A5-47AC-A9DA-1DBA1DFD437AQ26783249-CDCEB08F-E31B-4F7D-9800-3B73822A2544Q26853261-4AF3698E-110A-4BB8-98CF-6212C5602214Q26863326-1E03ED90-F333-4713-8495-6578269DF5ABQ26999887-B7956585-09B1-45EF-80A4-DBD566CD0E4CQ27851648-47FB794C-9758-4D0E-8285-AE512B29A66CQ27852353-F93A5CD3-AAD7-40B8-B29A-F5A5FD5BC11CQ27853042-1373A304-7A7D-4D3B-B7D0-71DF563D05B8Q27853057-4F49EEE2-5CFF-4856-9E84-B7A508C8FE95Q27853396-57D88A0F-D498-4573-A473-7157994538CEQ28253304-C25D3D3F-93D5-4912-9B66-2055B4FA0841Q28388902-3B25C26E-A889-4B40-BBD1-33592F0076C6Q28743591-6F026E71-947D-4077-980A-DB47EBF73884Q30367068-C9751B1A-B8CE-4FA8-967A-58212A0C3395Q30458424-38D4A86B-1403-41D2-945E-3FF4F47E5A56Q31114420-42761C0F-DBE7-41B7-A4B5-F6C7179C73F2Q33480990-F6C0E0B5-233E-4CA5-8DB9-C1F5B1DABC18Q33568168-A746F7C0-412F-4957-ACB9-511147AB139EQ33597740-C0EA61C5-F95C-4EFD-85C9-C7C5422E1793Q33656624-7F8C3DCA-02B8-41A1-BC3B-B2A9CDBE5A82Q33702243-FCF176A7-7226-49EB-857C-5C18C5BA99DFQ33750281-80FE1AE3-F6B0-4A2A-AED1-F2887C05DA4FQ33760910-07BBAFB6-A0FA-4972-8737-176A4B092D08Q33771120-9A0BA933-9549-4DB2-A84F-3E5D321F4C92Q33782114-89CA2B07-D55B-452A-B0D2-2ADDD8F987E4Q33782121-D8BA98DF-AA2A-4495-A8AF-7A08292AE23BQ33844111-3A56664A-F986-46E6-B569-FFE22A85E9C6Q33888762-4AD363E9-FA77-435A-8169-C7667DF0A407Q33909942-DCBB7F1E-CAF4-4864-859B-D5FAA5E5B595Q33982413-01AB1F00-D599-435F-8CDD-B1F149BD5261Q33987852-DE9A6D72-FBC4-4132-AC5B-A5973E4B7761Q34018753-CB5DCEC8-837D-4FE8-BC10-71904EC362B0Q34041618-C999FF2F-539B-409E-AF15-EA826DF16350Q34119098-2E2CF1A1-6092-4AE5-9671-5311F34D752DQ34123724-EE388A45-E049-4030-AD8B-65E02C201655Q34123904-0BE2C0D2-B786-497E-B18C-37F300FFDA44Q34209934-5636ED3A-7E1E-41A2-8D05-ABE51AA241A1
P2860
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@ast
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@en
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@nl
type
label
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@ast
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@en
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@nl
prefLabel
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@ast
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@en
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@nl
P2093
P356
P1476
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
@en
P2093
Alexandr Larin
Anthony P Tufaro
Christopher B Umbricht
David Sidransky
Eli Rosenbaum
Elizabeth H Holt
Giovanni Tallini
Joseph A Califano
Kathryn A Carson
Kerry J Rhoden
P304
P356
10.1210/JC.2005-0987
P407
P577
2005-09-20T00:00:00Z